Nobel Biocare, part of the Envista family of brands, has announced the acquisition of Versah®, a company focused on dental osteotomy and bone densification technologies. The acquisition brings Versah’s Densah® Burs and its Osseodensification technique into Nobel Biocare’s existing implant and regenerative portfolio, alongside the regenerative offerings of Osteogenics.
Versah’s technologies are designed to support implant site preparation approaches that may facilitate immediate implant placement and provisionalization in a broader range of clinical situations. In addition, the solutions are used in regenerative procedures, including sinus elevation and ridge expansion. The acquisition aligns with Nobel Biocare’s stated focus on science-driven implant and regenerative solutions.
Founded in 2014 and headquartered in Jackson, Michigan, Versah developed the patented Densah Bur technology for implant site preparation. Unlike conventional drilling protocols that remove bone, Densah Burs are designed to compact and autograft bone laterally during osteotomy preparation. This approach aims to support primary implant stability and expand treatment options, particularly in sites with limited bone density. The technology is supported by biomechanical, histological, and clinical research and has been adopted by clinicians internationally.
“We are thrilled to welcome Versah to Nobel Biocare,” said Stefan Nilsson, President of Nobel Biocare. “Their Densah Bur technology is grounded in significant scientific validation and represents an important advancement in how clinicians approach implant site preparation. Integrating this level of innovation reinforces our commitment to delivering evidence based solutions that support predictable, high quality patient care.”
Dr. Salah Huwais, founder of Versah, added: “Joining Nobel Biocare marks an exciting new chapter for Versah. With Nobel Biocare's global reach and strong clinical heritage, we can bring the benefits of Osseodensification to even more dental professionals and their patients. I’m looking forward to this next phase of innovation and growth together.”
According to Nobel Biocare, the acquisition reflects its ongoing strategy to broaden its regenerative and implant solutions portfolio and to support clinicians through continued research, innovation, and integration of digital and clinical workflows.
